AC Immune SA (ACIU) Stock Price, News, Quote & History

0&&s)if(o){var r,a=(r=e.newCount)>99;s.textContent=a?"99+":r+"",null===(t=s.parentElement)||void 0===t||t.classList.add(zt)}else s.style.display="block"},m=function(){d.refreshPanel().then(h).then(ee).catch((function(){}))};e.addEventListener("close-all-menus",(function(){xe(c)||u()})),c&&(m(),setInterval((function(){m()}),3e5),o?l&&l.addEventListener("mouseenter",(function(){p(),null==t||t.show()})):c.addEventListener("mouseenter",(function(){p(),null==t||t.show()})),c.addEventListener("mouseleave",(function(){u(),null==t||t.hide()}))),e.addElementListener(i,"click",(function(){Q("ybar","notification","",{elm:"btn",elmt:"block"===(null==s?void 0:s.style.display)?"newalert":"",subsec:"notification",itc:"1"})})),r&&Ee(e,r,"ybar","notification",{elm:"expand",subsec:"notifications",itc:"2"}),e.addElementListener(a,"focusin",(function(){i&&(i.checked=!0),null==a||a.classList.add("ybarMenuOpen")})),e.addElementListener(a,"focusout",u),e.addElementListener(n.tooltipContainer,"focusin",(function(){null==t||t.show()})),e.addElementListener(n.tooltipContainer,"focusout",(function(){null==t||t.hide()}));var f=e.getConfig().device,v=document.getElementById("ybar");v&&v.classList.contains("ybar-ytheme-crunch")&&(Qt=0);var y=new RegExp("[?&]notifications=1(&|#|$)");"desktop"===f&&i&&y.test(window.location.search)&&(i.checked=!0)};ye("ybar-mod-notification",(function(e){var n={isUH3:"crunch"===e.getConfig().ytheme,notifContainer:document.getElementById("notification-container"),notifBadge:document.getElementById("notif-badge"),notifMenu:document.getElementById("ybarNotificationMenu"),notifMenuOpener:document.querySelector("#ybarNotificationMenu + label"),notifDropdown:document.getElementById("notifDropdownContainer"),tooltipContainer:document.querySelector(".".concat(Ft)),notifLabel:document.querySelector(".".concat(Gt))};no(e,n)}))}()}};

NasdaqGM - Delayed Quote • USD

4.8300 +0.1800 (+3.87%)

At close: June 3 at 4:00 PM EDT

Key Events

Line

Candle

Baseline

Mountain

Bar

Advanced Chart

Loading Chart for ACIU

9/21 12:03 PM

DELL

Date
Close
Open
High
Low
Volume

Previous Close 4.6500
Open 4.8500
Bid 4.8000 x 100
Ask 4.8400 x 100
Day's Range 4.5901 - 4.9000
52 Week Range 1.9000 - 5.1400
Volume 509,093
Avg. Volume 828,315
Market Cap (intraday) 477.682M
Beta (5Y Monthly) 1.05
PE Ratio (TTM) --
EPS (TTM) -0.6800
Earnings Date Aug 2, 2024 - Aug 6, 2024
Forward Dividend & Yield --
Ex-Dividend Date --
1y Target Est 10.37

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. The company's SupraAntigen and Morphomer platforms are designed to generate biologics and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. It is developing Crenezumab, a humanized, conformation-specific monoclonal antibody used to slow Alzheimer's disease (AD) progression; and Semorinemab, an investigational monoclonal anti-Tau antibody that targets the N-terminal portion of the Tau protein and is designed to bind to Tau and slow its spread between neurons for the treatment of AD. The company is also developing ACI-24.060 for the treatment of down syndrome-related AD; ACI-7104.056, to treat Parkinson's disease; and ACI-35.030, designs to stimulate a patient's immune system to produce antibodies against pathological phosphorylated Tau. In addition, it is developing diagnostic programs, consisting of PI-2620, a Tau diagnostic for AD, as well as non-AD Tauopathies; and ACI-12589, a-sync PET tracer that supports the differential diagnosis of multiple system atrophy from other neurodegenerative disease. Further, the company is researching and developing Morphomer Tau aggregation inhibitors to evaluate candidates in AD and NeuroOrphan Tauopathies. Additionally, it has discovery and preclinical stage molecules targeting range of neurodegenerative diseases, which include diagnostics targeting TDP-43, alpha-synuclein, and NLRP3. The company has license agreements and collaborations with Genentech, Inc.; Janssen Pharmaceuticals, Inc.; Life Molecular Imaging SA; and Eli Lilly and Company. AC Immune SA was incorporated in 2003 and is headquartered in Lausanne, Switzerland.

www.acimmune.com

133

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

More about AC Immune SA

Recent News: ACIU

All SEC Filings

Corporate Changes & Voting Matters

Periodic Financial Reports

Proxy Statements

Compare

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

ACIUAC Immune SA

4.8300

+3.87%

Mkt Cap 477.682M

Industry Biotechnology

ANVSAnnovis Bio, Inc.

6.81

+3.97%

Mkt Cap 76.078M

Industry Biotechnology

CADLCandel Therapeutics, Inc.

8.37

-5.96%

Mkt Cap 249.058M

Industry Biotechnology

ADAPAdaptimmune Therapeutics plc

1.0700

-5.31%

Mkt Cap 273.451M

Industry Biotechnology

VCNXVaccinex, Inc.

7.11

+4.87%

Mkt Cap 11.264M

Industry Biotechnology

ANNXAnnexon, Inc.

4.5800

-5.18%

Mkt Cap 423.251M

Statistics: ACIU

Valuation Measures

Annual

As of 6/3/2024

Market Cap

476.69M
Enterprise Value

364.10M
Trailing P/E

--
Forward P/E

--
PEG Ratio (5yr expected)

--
Price/Sales (ttm)

26.05
Price/Book (mrq)

2.97
Enterprise Value/Revenue

22.18
Enterprise Value/EBITDA

--

Financial Highlights

Profitability and Income Statement

Profit Margin

0.00%
Return on Assets (ttm)

-20.85%
Return on Equity (ttm)

-36.68%
Revenue (ttm)

14.8M
Net Income Avi to Common (ttm)

-54.58M
Diluted EPS (ttm)

-0.6800

Balance Sheet and Cash Flow

Total Cash (mrq)

104.82M
Total Debt/Equity (mrq)

2.30%
Levered Free Cash Flow (ttm)

-24.21M

Research Analysis: ACIU

Company Insights: ACIU

Research Reports: ACIU

People Also Watch

CTMX CytomX Therapeutics, Inc.

1.7500

+2.94%

CRVS Corvus Pharmaceuticals, Inc.

2.2100

+2.31%

ALEC Alector, Inc.

5.03

+2.24%

AUTL Autolus Therapeutics plc

4.5000

+7.40%

ACRS Aclaris Therapeutics, Inc.

1.0400

+0.97%

PTGX Protagonist Therapeutics, Inc.

29.81

+5.90%

ADIL Adial Pharmaceuticals, Inc.

1.3100

-9.66%

BYSI BeyondSpring Inc.

2.7800

+5.70%

ANVS Annovis Bio, Inc.

6.81

+3.97%

MRSN Mersana Therapeutics, Inc.

2.3500

+0.86%

INMB INmune Bio, Inc.

9.63

+1.90%

ADVM Adverum Biotechnologies, Inc.

7.75

-2.15%

EDSA Edesa Biotech, Inc.

4.5900

+6.00%

AFMD Affimed N.V.

7.33

+68.51%

CLSD Clearside Biomedical, Inc.

1.2900

-7.86%

ALDX Aldeyra Therapeutics, Inc.

3.8400

-0.52%

AC Immune SA (ACIU) Stock Price, News, Quote & History - Yahoo Finance (2024)

Full Time Employees

Fiscal Year Ends

Sector

Industry

Profitability and Income Statement

Balance Sheet and Cash Flow